| Literature DB >> 29150078 |
Gaëlle Milanole1, Bo Gao1, Audrey Paoletti2, Grégory Pieters1, Christophe Dugave1, Eric Deutsch3, Sofia Rivera4, Frédéric Law5, Jean-Luc Perfettini5, Emilie Mari6, Estelle Léonce6, Céline Boutin6, Patrick Berthault7, Hervé Volland8, François Fenaille8, Thierry Brotin9, Bernard Rousseau10.
Abstract
Although Non-Small Cell Lung Cancer (NSCLC) is one of the main causes of cancer death, very little improvement has been made in the last decades regarding diagnosis and outcomes. In this study, a bimodal fluorescence/129Xe NMR probe containing a xenon host, a fluorescent moiety and a therapeutic antibody has been designed to target the Epidermal Growth Factor Receptors (EGFR) overexpressed in cancer cells. This biosensor shows high selectivity for the EGFR, and a biological activity similar to that of the antibody. It is detected with high specificity and high sensitivity (sub-nanomolar range) through hyperpolarized 129Xe NMR. This promising system should find important applications for theranostic use.Entities:
Keywords: Biosensor; Cetuximab; EGFR; Hyperpolarized xenon; NMR
Mesh:
Substances:
Year: 2017 PMID: 29150078 DOI: 10.1016/j.bmc.2017.11.002
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641